Chiral Resolution, Absolute Configuration Assignment, and Genotoxicity Evaluation of Racemic 3,4-Dihydroquinazoline as a Novel Anticancer Agent

Table 2

Cytotoxicity of racemate (±)-KCP-10043F and its two enantiomers against human cancer cell lines.

Compound	Cytotoxicity (IC50: μM)
	A549^a,b	HT-29^c	PANC-1^d
(R)-(−)-KCP10043F	9.35 ± 0.29	5.52 ± 0.46	12.96 ± 0.82
(S)-(+)-KCP10043F	9.78 ± 0.11	5.37 ± 0.31	10.60 ± 0.13

^aHuman lung adenocarcinoma cell line; ^bIC₅₀ of racemate (±)-KCP-10043F = 7.0 ± 0.1 μM; ^chuman colorectal adenocarcinoma cell line; ^dhuman pancreatic cancer cell line.